A randomised open label study to evaluate the safety and efficacy of imiquimod 5% cream applied 3 times per week for 8 or 12 weeks in the treatment of low risk nodular basal cell carcinoma.

Trial Profile

A randomised open label study to evaluate the safety and efficacy of imiquimod 5% cream applied 3 times per week for 8 or 12 weeks in the treatment of low risk nodular basal cell carcinoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2011

At a glance

  • Drugs Imiquimod (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Oct 2007 Final results have been published (1087409)
    • 23 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top